As for the prospect of facing sooner-than-expected generic pricing pressure from Vyndaqel copycats in Europe, BridgeBio CEO Neil Kumar said that his company is counting on continued efforts to set ...
BBIO’s Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. This candidate positions BBIO against Pfizer’s Tafamidis and Alnylam’s Amvuttra. Its US uptake keeps ...
BridgeBio has revealed new pivotal trial data for Attruby (acoramidis) along with results from an indirect comparison to Pfizer’s Vyndamax (tafamidis), as the former company looks to continue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results